Summary
Danaher Corporation (DHR) has announced the completion of its acquisition of General Electric Company's (GE) Biopharma business. This significant transaction, valued at approximately $21.0 billion in cash plus the assumption of $0.4 billion in pension liabilities, closed on March 31, 2020. The acquisition was made through an equity and asset purchase agreement, integrating GE's Biopharma business into Danaher's operations. This acquisition marks a substantial expansion for Danaher, particularly within the life sciences sector. Investors should note that the audited financial statements for the acquired Biopharma Business for the years ended December 31, 2019 and 2018 have been filed as an exhibit. Pro forma financial information is expected to be filed at a later date, within 71 days of the report's filing.
Key Highlights
- 1Danaher Corporation completed the acquisition of GE's Biopharma business on March 31, 2020.
- 2The total transaction value is approximately $21.0 billion in cash.
- 3Danaher also assumed approximately $0.4 billion in pension liabilities.
- 4The acquisition was completed through an equity and asset purchase agreement.
- 5Audited financial statements for the acquired Biopharma Business for 2019 and 2018 are included as exhibits.
- 6Pro forma financial information will be filed by amendment within 71 days.